
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
The vaccine combines NY-ESO-1 with IMX, a potent immune-system stimulator that consists of cholesterol, phospholipids and saponin.






